TCRT ALAUNOS THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ALAUNOS THERAPEUTICS INC reported revenue of $0, net income of −$952K and diluted EPS of −$0.41; over the last four quarters revenue was $3.00K and net income −$4.01M; for the fiscal year ended December 2025 revenue was $5.00K, down 50.0% on the year before.
TCRT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $5.00K, gross profit n/a, operating income −$4.23M, net income −$4.18M (margin -83520.0%), EPS −$2.20
- Fiscal year ended Dec 2024: revenue $10.0K, gross profit n/a, operating income −$4.81M, net income −$4.68M (margin -46790.0%), EPS −$2.92
- Fiscal year ended Dec 2023: revenue $5.00K, gross profit n/a, operating income −$34.3M, net income −$4.68M (margin -93580.0%), EPS −$21.97
- Fiscal year ended Dec 2022: revenue $2.92M, gross profit n/a, operating income −$35.1M, net income −$37.7M (margin -1291.2%), EPS −$2.61
- Fiscal year ended Dec 2021: revenue $398K, gross profit n/a, operating income −$77.5M, net income −$78.8M (margin -19786.7%), EPS −$0.37
TCRT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$952K, EPS −$0.41
- Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$1.01M, EPS −$0.59
- Quarter ended Dec 31, 2025 (from the annual report): revenue $3.00K (down 40.0% year over year), net income −$893K, EPS −$0.35
- Quarter ended Sep 30, 2025: revenue $0, net income −$1.16M, EPS −$0.55
- Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$1.05M, EPS −$0.63
- Quarter ended Mar 31, 2025: revenue $2.00K (up 100.0% year over year), net income −$1.07M, EPS −$0.67
- Quarter ended Dec 31, 2024 (from the annual report): revenue $5.00K (up 400.0% year over year), net income −$741K, EPS −$0.46
- Quarter ended Sep 30, 2024: revenue $0, net income −$1.13M, EPS −$0.70
- Quarter ended Jun 30, 2024: revenue $4.00K (up 0.0% year over year), net income −$1.13M, EPS −$0.71
- Quarter ended Mar 31, 2024: revenue $1.00K, net income −$1.68M, EPS −$1.05
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.00K, net income $22.6M, EPS −$10.55
- Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$8.48M, EPS −$5.30
- Quarter ended Jun 30, 2023: revenue $4.00K, net income −$8.77M, EPS −$5.49
- Quarter ended Mar 31, 2023: revenue $0, net income −$10.0M, EPS −$0.63
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$9.16M, EPS −$2.47
- Quarter ended Sep 30, 2022: revenue $2.91M (up 631.4% year over year), net income −$8.85M, EPS −$0.04
- Quarter ended Jun 30, 2022: revenue $0, net income −$9.93M, EPS −$0.05
- Quarter ended Mar 31, 2022: revenue n/a, net income −$9.79M, EPS −$0.05
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$11.8M, EPS −$0.05
- Quarter ended Sep 30, 2021: revenue $398K, net income −$22.7M, EPS −$0.11
TCRT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$2.87M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$4.97M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$30.1M, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow −$29.2M, share buybacks $45.0K
- Fiscal year ended Dec 2021: operating cash flow −$61.5M, share buybacks $0
TCRT balance sheet
- Jun 30, 2026: cash $124K, total assets $1.52M, total liabilities $864K, shareholders' equity $652K
- Mar 31, 2026: cash $354K, total assets $1.88M, total liabilities $595K, shareholders' equity $1.29M
- Dec 31, 2025: cash $1.39M, total assets $2.97M, total liabilities $813K, shareholders' equity $2.15M
- Sep 30, 2025: cash $1.94M, total assets $3.72M, total liabilities $921K, shareholders' equity $2.80M
- Jun 30, 2025: cash $2.88M, total assets $4.74M, total liabilities $1.07M, shareholders' equity $3.66M
- Mar 31, 2025: cash $319K, total assets $2.12M, total liabilities $1.06M, shareholders' equity $1.06M
- Dec 31, 2024: cash $1.09M, total assets $2.76M, total liabilities $692K, shareholders' equity $2.06M, long-term debt $0
- Sep 30, 2024: cash $1.68M, total assets $3.55M, total liabilities $826K, shareholders' equity $2.72M
What is TCRT's revenue?
ALAUNOS THERAPEUTICS INC reported $3.00K of revenue over its last four quarters, through June 30, 2026.
Is TCRT profitable?
No. ALAUNOS THERAPEUTICS INC lost $4.01M over the last four quarters.
What is TCRT's EPS?
Diluted earnings per share over the last four quarters were −$1.90; −$0.41 in the latest quarter.